• Tidak ada hasil yang ditemukan

Supplemental Digital Content

N/A
N/A
Info
Unduh - Bebas
Protected

Academic year: 2024

Membagikan "Supplemental Digital Content"

Copied!
2
0
0

Memuat.... (Lihat teks lengkap sekarang)

Unduh sekarang ( 2 Halaman )

Teks penuh

(1)

Supplemental Digital Content

TABLE 2. Panel A and B of this table compare the analysis of coagulation screens in term (A) and preterm (B) infants, which were obtained prior to catheter placement at defined time periods. The data (mean and  2 standard deviations) are presented along with the normal values. The reference data were obtained at various specific time points: ^ d1 # d5, ° d30, * d90 (Andrew et al.); ^ d1, # d3, * 1 month-1year (Monagle et al. using the Stago methodology). Note: values from Andrew et al. validated for 30-36 weeks of gestational age. Abbreviations: d, day; aPTT, activated partial thromboplastin time; AT-III, anti-thrombin III.;

n.a., not applicable.

A.

Coagulation Parameter

Age

d 1-2^ d 3-5# d 6-30° d 31-180*

aPTT (s) Cases

51.9 (30.8–72.9) 41.6 (27.2–56.0) 35.3 (31.7–38.8) -

considered to be abnormal:

n=2 (out of 3)

considered to be abnormal:

n=1 (out of 2)

considered to be abnormal:

n=0 (out of 2) -

Controls

46.1 (29.2–62.9) - - 38.7 (31.3–46.0)

considered to be abnormal:

n=3 (out of 6) - - considered to be abnormal:

n=1 (out of 4)

Andrew et al. 42.9 (31.3–54.5) 42.6 (25.4–59.8) 40.4 (25.6–55.2) 37.1 (24.1–50.1)

Monagle et al. 38.7 (34.3–44.8) 36.3 (29.5–42.2) - 39.3 (35.1–46.3)

Fibrinogen (g/l) Cases

2.23 (1.56–2.89) 2.44 (0.12–4.76) 1.72 (1.32–2.12) -

considered to be abnormal:

n=2 (out of 3)

considered to be abnormal:

n=1 (out of 2)

considered to be abnormal:

n=1 (out of 2) -

Controls

1.78 (0.88–2.67) - - 3.43 (2.37–4.49)

considered to be abnormal:

n=5 (out of 6) - - considered to be abnormal:

n=1 (out of 4)

Andrew et al. 2.83 (1.67–3.99) 3.12 (1.62–4.62) 2.70 (1.62–3.78) 2.43 (1.07–3.79)

Monagle et al. 2.80 (1.92–3.74) 3.30 (2.83–4.01) - 2.42 (0.82–3.83)

AT-III (%) Cases

61 (44–78) 37 (29–44) 53 (41–54) -

considered to be abnormal:

n=1 (out of 3)

considered to be abnormal:

n=2 (out of 2)

considered to be abnormal:

n=2 (out of 2) -

Controls

51 (15–86) - - 58 (42–74)

considered to be abnormal:

n=4 (out of 6) - - considered to be abnormal:

n=4 (out of 4)

Andrew et al. 63 (39–87) 67 (41–93) 78 (48–108) 97 (73–121)

Monagle et al. 76 (58–90) 74 (60–89) - 109 (72–134)

(2)

B.

Coagulation Parameter

Age

d 1-2 d 3-5# d 6-30° d 31-180*

aPTT (s) Cases

74.3 (13.2–135.5) 40.2 (n.a.) 44.9 (24.8–65.0) 39.4 (33.1–45.6)

considered to be abnormal:

n=2 (out of 5)

considered to be abnormal:

n=0 (out of 1)

considered to be abnormal:

n=0 (out of 2)

considered to be abnormal:

n=0 (out of 3) Controls

72.1 (0–155.3) 49.0 (22.7–75.3) 36.7 (n.a.) -

considered to be abnormal:

n=3 (out of 14)

considered to be abnormal:

n=0 (out of 2)

considered to be abnormal:

n=0 (out of 1)

-

Andrew et al. 53.6 (27.5–79.4) 50.5 (26.9–74.1) 44.7 (26.9–62.5) 39.5 (28.3–50.7)

Fibrinogen (g/l) Cases

1.54 (1.09–1.98) 2.49 (n.a.) 2.27 (1.37–3.16) 4.79 (4.54–5.04)

considered to be abnormal:

n=2 (out of 4)

considered to be abnormal:

n=0 (out of 1)

considered to be abnormal:

n=0 (out of 2)

considered to be abnormal:

n=2 (out of 2) Controls

1.93 (0–4.44) 1.62 (0–3.58) 2.71 (n.a.) -

considered to be abnormal:

n=8 (out of 14)

considered to be abnormal:

n=1 (out of 2)

considered to be abnormal:

n=0 (out of 1)

-

Andrew et al. 2.43 (1.50–3.73) 2.8 (1.60–4.18) 2.54 (1.50–4.14) 2.46 (1.50–3.52)

AT-III (%) Cases

31 (0–66) 54 (n.a.) 47 (8–85) 56 (11–102)

considered to be abnormal:

n=1 (out of 5)

considered to be abnormal:

n=0 (out of 1)

considered to be abnormal:

n=1 (out of 2)

considered to be abnormal:

n=1 (out of 3) Controls

28 (10–47) 39 (0–84) 24 (n.a.) -

considered to be abnormal:

n=1 (out of 14)

considered to be abnormal:

n=0 (out of 2)

considered to be abnormal:

n=1 (out of 1)

-

Andrew et al. 38 (14–62) 56 (30–82) 59 (37–81) 83 (45–121)

Referensi

Unduh sekarang ( PDF - 2 Halaman - 107.34 KB )

Dokumen terkait

Supplemental Digital Content Table 7. Associations of interventions and outcome variables with administration of vasopressor prior to CVC placement, in those receiving vasopressors.

A modified goal directed resuscitation algorithm incorporating the SpO2 and MAP goals was followed for patients randomized to EGDT in whom ScvO2 central venous catheter insertion was

Supplemental Digital Content Figure 1.2: MLH1 staining (200x magnification)

Teaching Case #5-Hysterectomy, Normal MMR variable MSH2 and MSH6 expression Supplemental Digital Content Figure 5.1 a-b: MSH2 staining 40x magnification.. Some regions of the tumor

SUPPLEMENTAL DIGITAL CONTENT 3

SUPPLEMENTAL DIGITAL CONTENT 3 Table S3-A: Associations of any leisure-time walking with urban form characteristics, psychosocial factors and their interaction n=736a,b,c.. All

(1)Supplemental Digital Content 1

Change in heart rate A, cardiac index B, systemic vascular resistance index C, stroke index D, left cardiac work index E, augmentation index F, augmentation index adjusted to heart rate

SUPPLEMENTAL DIGITAL CONTENT 4.

b Hazard ratios calculated using Cox proportional hazards models with age as the time scale and adjusted using inverse probability weights derived from a logistic regression model

24 Supplemental Digital Content 2. Events of Interest Identification Algorithms 1. General flow chart for case identification algorithm

b: How to apply case rule out criteria to identify non-cases  Search for case-rule out criteria based on all pre-specified ICD-9 codes in all clinical settings Outpatient, ED, and

SUPPLEMENTAL DIGITAL CONTENT 2. Patients Design Characteristics of the Included Articles Author Selection Criteria Number of Patients

Exclusion: unacceptable FU data, cyst >30mm, detectable MN or initial MPD >5mm 201 35 resected 166 non-resected 62.6 9.18 111:90 Symptomatic: 40 US, EUS, CT, ERCP, MRCP Diagnosis of

1 Table, Supplemental Digital Content 1 Anti-HBsAb geometric mean concentrations (IU/L) for PP population of neonates in Stratum 1 and 2, and in Substratum 1a and 1b at Months 2, 7 and 12

mean=arithmetic mean of log10- transformed antibody concentrations, N = number of participants in PP population; HBsAb = hepatitis B surface antibody; * statistically significant;